This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
Phase II Study is to Evaluate the Safety and tolerability of AL3810 in combination with carboplatin plus (+) etoposide in untreated participants with ES-SCLC. Phase III Study is to Evaluate the efficacy of AL3810 in combination with carboplatin plus (+) etoposide in untreated participants with ES-SCLC.
Epistemonikos ID: 18018321a0b675c4bd0ea8c6ab654891b7a1e218
First added on: May 07, 2024